This study was aimed at determining whether the peripheral benzodiazepine receptor (PBZDR), which is abundantly expressed on mononuclear phagocytes, is involved in host defense mechanisms depending on phagocyte membraneassociated NADPH-oxidase complex. Analysis by reversible and covalent binding of PBZDR expression on human neutrophils shows that it is modulated during NADPHoxidase activation with phorbol 12-myristate 13-acetate. Based on a series of 17 patients with chronic granulomatous disease (CGD), results show that PBZDR expression is dramatically impaired in X-linked CGD, an inherited disorder due to a mutation on the gene coding for cytochrome OME BENZODIAZEPINE molecules with characteris-S tic structural features interact with binding sites not affected by y-aminobutyric acid (GABA), mainly localized in peripheral organs, and thereafter named peripheral benzodiazepine receptors (PBZDR).' In a previous study, we demonstrated that macrophages exhibit a high density of PBZDR' and afforded evidence that this receptor was involved in the regulation of macrophage oxidative metabolism,' a function required for effective microbial killing: Human polymorphonuclear neutrophils (PMN) have been reported to express stereospecific PBZDR.' In this report, we show that the expression of PBZDR is altered in PMN from patients with X-linked chronic granulomatous disease (CGD),6 an inherited phagocyte disorder characterized by a deficiency in the heavy @ chain (91 Kd) of the cytochrome b,,, NADPH-oxidase ~omponent'.~ associated with the nonexpression of the 22-Kd 01 subunit, despite the presence of the corresponding messenger RNA (mRNA)." By contrast, PBZDR expression is unaffected in PMN of autosomal recessive CGD, which bear normal cytochrome b5,* but are defective in oxidase cytosolic activation factors.""' We further demonstrate that NADPH-oxidase activation of normal PMN is associated with a significant modulation of PBZDR.
cases). According to clinical characteristics, patients were classified into two groups: (1) those having clinically mild CGD and receiving only standard maintenance therapy (trimethoprim-sulfamethoxazole, and itraconazol as antifungal agent) (eight patients), and (2) those with clinically severe CGD, ie, having aspergillus pneumonia and/or liver abscess and receiving major antibiotherapy (amphotericin B) (nine patients). In eight cases, including AR+-CGD and X-CGD, mothers were tested. Fourteen healthy volunteers recruited among the blood donors of the Necker hospital (Paris, France) blood bank served as controls.
With informed consent according to approved protocol, patient and normal volunteer peripheral blood was drawn; PMN were isolated from heparinized blood (10 U/mL Liquemine; Roche, Paris, France) by Plasmagel (Roger Bellon Laboratories, Paris, France) sedimentation for 30 minutes at 37°C and Ficoll-Hypaque density gradient centrifugation. Freshly isolated PMN (3.5 x 10' cells, IO' cells/mL) from a normal subject were incubated at 37°C for 7 minutes in Hanks Balanced Salt Solution (HBSS) with 0.5 pg/mL phorbol 12-myristate 13-acetate (PMA; Sigma Chemical, St Louis, MO) for activation, or with the corresponding volume of dimethylsulfoxide for resting PMN. Cells were cooled for 4 minutes at 4"C, then washed twice in HBSS, resuspended in lysing solution ( 5 mmol/L Tris-HC1 pH 7.5, 5 mmol/L NaC1, 1 mmol/L dithiothreitol, 1 mmol/L phenylmethylsulfonyl fluoride, 0.1 mmol/L EDTA, and 0.25 mol/L sucrose), and broken using a Polytron homogenizer (Kinematica AG, Littau, Switzerland) at 4°C for 15 minutes. Nuclei and unbroken cells were eliminated as a pellet after one centrifugation for 10 minutes at 800g. The supernatant was centrifuged during 90 minutes at 100,OOOg. and the final pellet, termed membrane fraction, was resuspended in the lysis solution at a concentration of 3 to 4 mg protein/mL (as determined by using the protein assay reagent containing bicinchoninic acid [Pierce Chemical, Rockford, IL]) and stored at -7OOC where it remained stable for at least 2 to 3 months. Alternatively, small samples of PMN from normal or CGD subjects were sonicated three times for 15 seconds in the same buffer. After centrifugation (Eppendorf microcentrifuge, 10 minutes, 15,OOOg) to remove granules and nuclei, the supernatant was centrifuged in a Beckman Airfuge (10 minutes, 150,OOOg) to obtain a PMN membrane pellet. 
Cell and membranepreparations.

PERIPHERAL BENZODIAZEPINE RECEPTOR IN CGD
Gubrbmy, RhBne-Poulenc Santt, France), in a total volume of 0.5 mL of Dulbecco's potassium phosphate buffer (PBS), pH 7.4 at 0 to 4OC for 30 minutes. Incubation was terminated by filtration over GF/B glass fiber filters (Whatman) under vacuum and washed three times with 3 mL ice-cold PBS. Radioactivity of the oven-dried filters was counted by scintillation spectrometry. Specific binding was defined as total binding minus nonspecific binding observed in the presence of 5 pmol/L unlabeled PK-11195.
[3H]-PK-l 1195 (66 Ci/mmol, C.E.A.) (10 to 200 nmol/L) reversible binding was measured on membrane preparations at 50 pg protein/mL in 0.5 mL PBS at 0 to 4°C for 45 minutes in the presence and absence of 5 pmol/L unlabeled PK-11195. After vacuum filtration over GF/C glass fiber filters (Whatman) and three washes with 3 mL ice-cold PBS, filters were dried and radioactivity was counted. Covalently labeled membranes from control subjects were analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) (12%) overnight at 50 mV. The gel was further fixed, stained, and soaked in Amplify fluorographic reagent (Amersham, Buckinghamshire, UK). The gel was dried and autoradiography was performed by exposing Kodak X-Omat-AR5 film (Eastman Kodak, Rochester, NY) to the gel at -7OOC for 48 hours. Alternatively, after electrophoresis (40 pg protein/lane), proteins were electroblotted for 15 hours at 100 mA in a buffer (pH 8.3) containing 25 mmol/L Tris-HC1, 192 mmol/L glycine, and 20% (vol/vol) methanol, to nitrocellulose membranes (0.22 pm, Schleicher and Schuell, Dassel, FRG). The nitrocellulose membranes were successively sprayed with Amplify-Spray (Amersham) and autoradiographed.
The significance of differences between groups to be compared was analyzed by Student's t-or chi-squared (x') tests where appropriate.
Electrophoresis, Western blotting, and autoradiography.
Statistical analysis.
RESULTS
Expression of PBZDR on neutrophils of CGD patients.
We assessed the level of expression of high affinity PBZDR on isolated P M N from 17 CGD patients, 9 with an autosomal recessive mode of transmission (AR+-CGD) and 8 with X-linked transmission (X-CGD), and compared the results with those of a control group of 14 healthy adult volunteer blood donors. Binding studies with the prototypical PBZDR ligand [3H]-Ro5-4864 (Fig 1) showed that a single class of high affinity binding sites was detectable on intact human PMN. AR'-CGD patients and control individuals displayed a wide intragroup variability, but showed no difference either in mean affinity (kd f SEM) or in mean maximal number (Bmax f SEM) of PBZDR expressed on the surface of P M N (controls: kd = 51. patients and 1 of 14 control subjects expressed less than 250,000 receptors per cell (ie, mean control Bmax -2 SD). In contrast, there was a significantly reduced level of PBZDR expressed on PMN from X-CGD patients (Bmax = [2.9 f 1.41 IO5 sites/cell). Six of eight X-CGD patients expressed less than 250,000 receptors per cell, including three who expressed no measurable specific high affinity
[3H]-Ro5-4864 binding (P < .001 is the significance of the difference in Bmax measured for the X-CGD group when compared with controls, and P < .01 when compared with AR+-CGD, using x2 test). The level of PBZDR expression was not influenced by the clinical status of the patients a t the time of testing, since patients with mild (or severe) CGD were equally distributed among those having nil (or low PBZDR) and those having normal or high levels of PBZDR. As compared with normal subjects, those X-CGD patients who did bind specifically some [ Efect of NADPH-oxidase activation on PBZDR expression. To further investigate the involvement of PBZDR in phagocyte oxidative responsiveness, we compared its level of expression in membranes prepared from normal human PMN in resting state or after PMA activation, [3H]-PK-1 1195, the specific PBZDR antagonist that binds to a different subsite of the PBZDR, was used instead of Ro5-4864 since specific binding of the latter compound was altered during the course of membrane preparation, presumably due to the sensitivity of its binding site to thiol reagents such as dithiothreitol." As shown in Table 1 , PMA activation of PMN was reflected by a modulation of [3H-PK-l 1 195 specific binding, with a threefold decrease in affinity and a concomitant threefold increase in the number of receptor sites per milligram of membrane protein.
The molecular weight of the neutrophil PBZDR was determined by covalent binding of membrane preparations with the photosensitive ligand ['HI-PK-14105 under ultraviolet irradiation at 365 nm. Equivalent protein amounts of covalently labeled membranes in the absence or presence of an excess of PK-11195 were electrophoresed; autoradiography of the gel essentially showed, in both resting and PMA-activated PMN membranes, a specifically labeled protein band with an apparent molecular mass of 18 Kd, and two faintly labeled bands at 13 and 11.5 Kd, respectively (Fig 2) . The latter bands corresponded to heavily loaded protein bands on the Coomassie blue-stained gel, while the former was undetectable (not shown). Interestingly, the density of the radiolabeled 18-Kd band (as measured by laser densitometry) of PMA-activated membranes was twofold that of resting membranes, showing that the extent of covalent binding with ['H]-PK-14105 was in good keeping with the reversible binding measured with Autoradiographic analysis of covalently labeled PMN membranes from CGD patients after SDS-PAGE and Western blotting (Fig 3) showed that compared with a control subject, similar patterns were obtained for AR'-CGD but not for representative X-CGD patients whose membranes did not express the 18-Kd radiolabeled band. Because the
Molecular characterization of PBZDR.
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Resting PMA-activated 21 and PMA-activated (lanes 3 and 4) PMN. Membranes were bound in the presence (lanes 1 and 3) or in the absence (lanes 2 and 4) of excess unlabeled PK-11195.
X-CGD case with a level of [3H]-Ro5-4864 reversible binding comparable with that of normal subjects also expressed the 18-Kd covalently radiolabeled band, we can consider him as a variant for PBZDR expression.
DISCUSSION
These results demonstrate an altered expression of PBZDR associated with the human genetic phagocytic disorder CGD. This alteration is specific for the X-linked form of CGD. The level of PBZDR expression is not dependent on the clinical status of the patients and remained unchanged when analyzed at intervals of several months (data not shown).
The fact that the alteration in PBZDR expression is specific for the X-linked form of CGD and not demonstrable in AR+-CGD suggests a possible link between this receptor and cytochrome b,,, expression at the membrane of PMN. The upregulation of the membrane expression of PBZDR on PMA stimulation of the respiratory burst, measured by both covalent and reversible binding, is also in favor of this possibility. Nevertheless, the molecular mass of PBZDR (18 Kd) is distinct from any of the cytochrome b,,, 91-Kd and 22-Kd chains that were not photo-affinity labeled. Moreover, the fact that PBZDR expression is considerably reduced but The ubiquity of PBZDR in mammalian cells does not argue against its possible interaction with the phagocyterestricted NADPH-oxidase complex. Instead, on the one hand it is in keeping with the findings of Pick and Gabda2' that nonphagocytic cells bear a cytochrome b,,,-like membrane-associated component and, on the other hand, the observation that the mRNA for the 22-Kd chain of the cytochrome b,,, is found in all cell types."
At present there is no available information on the gene coding for PBZDR, which has not been cloned (see Note Added in Proof). However, an alternative hypothesis for the apparent link between the expressions of cytochrome b,,, and PBZDR may be the possible location of the gene coding for PBZDR in the vicinity of the gene coding for the /3 subunit on the X-chromosome. Indeed, the CGD mutation is known to affect a more or less extended region on the X-chromosome with X-linked CGD sometimes being associated with other genetic disorders (such as Duchenne myopathy24 and Mac Leod syndrome',).
The fact that PBZDR can also accommodate the mixed type anxiolytic ligands, such as Valium (diazepam, Sigma), further suggests that PBZDR could possibly mediate neuroimmune interactions affecting host-defense mechanisms.
NOTE ADDED IN PROOF
Recently, Sprengel et al ( 
